Closed · W81XWH-21-NFRP-CTCA · CFDA 12.420 · Discretionary
DOD Neurofibromatosis, Clinical Trial Consortium Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 29, 2021
- Close date
- 1
- Expected awards
The verdict
DOD Neurofibromatosis, Clinical Trial Consortium Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 1
- expected award
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DOD Neurofibromatosis, Clinical Trial Consortium Award - is cataloged under number W81XWH-21-NFRP-CTCA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as closed, first posted on August 20, 2021. The funding category is Discretionary, delivered as a other.
Award economics. The award range on file is Varies by applicant. The agency has projected $25.0 million in total estimated funding for this announcement. It expects to issue 1 award. If the agency funds the expected 1 award from the $25.0 million estimated pool, the average award works out to roughly $25.0 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on October 29, 2021. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
October 29, 2021
Posted
August 20, 2021
Est. Total Funding
$25,000,000
Expected Awards
1
Instrument
Other
Description
The NFRP Clinical Trial Consortium Award mechanism was first offered in FY06, and subsequently in FY11 and FY16, with awards being made as grants or cooperative agreements. This FY21 research announcement is being offered through a different type of award mechanism, a Research Other Transaction Award (rOTA) under the authority of 10 USC 2371. The FY21 NFRP Clinical Trial Consortium Award is intended to support a major goal/product-driven consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the rOTA are the conception, design, development, and conduct of collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis.Research Other Transaction Agreement The principal purpose of a rOTA is to carry out non-duplicative basic, applied, and advanced research projects rather than the acquisition of property or services for the direct benefit or use of the government. The anticipated deliverables to the government under a rOTA are reports on research rather than prototypes. Additionally, a rOTA has several features that differ from those of the previous award types offered for the NFRP Clinical Trial Consortium. The rOTA requires resource sharing, with government funds not to exceed the total amount provided by other parties to the maximum extent practicable. Offerors will be required to demonstrate how resources (e.g., cash and non-cash) will be made available for this project. Please also note that the government’s funds will not be front-loaded, with certain matches being required before additional government funds are made available. The rOTA is intended to promote the use of best business practices and to foster relationships among performers from different sectors. In addition, as a matter of DOD policy, rOTAs may only be awarded when one or more for-profit firms are to be involved either in the: (1) performance of the research project(s) or (2) commercial application of the research results. A consortium should either include, collaborate with, or involve one or more for-profit firms in addition to state or local government agencies, institutions of higher education, or other nonprofit organizations. General Information The NFRP Clinical Trial Consortium requires collaboration of multiple organizations and individuals for the purpose of rapidly executing clinical trials. Therefore, the offeror must have a demonstrated history of collaborative research in such a structure. Studies supported by this award will include: Phase 1 and Phase 2 trials which are the primary focus of this award. Certain observational trials with appropriate justification and at the discretion of the USAMRAA Agreements Officer. To be included, observational studies will require review by the NFRP Advisory Board and Program Office. Correlative studies as a part of a trial funded by this award may be considered. Support for repositories/tissue collection from NFRP Clinical Trial Consortium clinical trials supported may be considered based on the availability of long-term funding, priorities, and resources. The participants will be jointly responsible for prioritizing, proposing, conducting, and analyzing Phase I and Phase II clinical trials focused on therapeutic interventions for NF1, NF2, and schwannomatosis. A final report cumulating the findings for all supported clinical trials will provided at the end of the term of the agreement.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
Jason D Kuhns Agreements Officer Phone 3016191861
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |